Novartis AG NVS:NYSE

RT Quote | Last NASDAQ LS, VOL From CTA | USD

After Hours: Last | 05/01/24 EDT

97.00

-0.50 (-0.51%)

Volume

153,808

97.50UNCH (UNCH)

Volume

1,117,771

52 week range

88.86 - 108.78

Open96.97
Day High97.87
Day Low96.71
Prev Close97.13
52 Week High108.78
52 Week High Date01/22/24
52 Week Low88.86
52 Week Low Date07/07/23

Key Stats

Market Cap213.518B
Shares Out2.19B
10 Day Average Volume2.11M
Dividend3.74
Dividend Yield3.84%
Beta0.54
YTD % Change-3.44

KEY STATS

Open96.97
Day High97.87
Day Low96.71
Prev Close97.13
52 Week High108.78
52 Week High Date01/22/24
52 Week Low88.86
52 Week Low Date07/07/23
Market Cap213.518B
Shares Out2.19B
10 Day Average Volume2.11M
Dividend3.74
Dividend Yield3.84%
Beta0.54
YTD % Change-3.44

RATIOS/PROFITABILITY

EPS (TTM)4.41
P/E (TTM)22.09
Fwd P/E (NTM)13.49
EBITDA (TTM)21.93B
ROE (TTM)19.86%
Revenue (TTM)47.733B
Gross Margin (TTM)74.61%
Net Margin (TTM)19.09%
Debt To Equity (MRQ)68.55%

EVENTS

Earnings Date07/18/2024
Ex Div Date03/07/2024
Div Amount3.7395
Split Date-
Split Factor-

Latest On Novartis AG

FTC challenges 'junk' patents held by 10 drugmakers, including for OzempicApril 30, 2024CNBC.com
Watch CNBC's full interview with Novartis CEO Vas Narasimhan on earnings and weight loss drugsApril 23, 2024CNBC.com
Novartis CEO: Here's why we boosted our full-year guidanceApril 23, 2024CNBC.com
Stocks making the biggest moves midday: Spotify, JetBlue, Danaher and moreApril 23, 2024CNBC.com
Why this is perfect time to buy health-care stocks, one financial advisor saysApril 23, 2024CNBC.com

Content From Our Affiliates

FTC expands patent listing challenges for drugsApril 30, 2024TipRanks
Biotech Sector: M&A Fuels Renewed ExcitementApril 30, 2024TipRanks
Novartis price target raised to CHF 108 from CHF 104 at UBSApril 24, 2024TipRanks
BeiGene price target raised to $236 from $235 at TD CowenApril 24, 2024TipRanks
Novartis reports FDA approves Lutathera for pediatric GEP-NETsApril 23, 2024TipRanks

Profile

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided...

Joerg Reinhardt Ph.D.

Independent Non-Executive Chairman of the Board

Vasant Narasimhan M.D.

Chief Executive Officer, Member of the Executive Committee

Harry Kirsch

Chief Financial Officer, Member of the Executive Committee

Address

Lichtstrasse 35

Basel

4056

Switzerland

https://www.novartis.com/

Top Peers

SYMBOL	LAST	CHG	%CHG
AZN AstraZeneca PLC	76.41	UNCH	UNCH
RHHBY Roche Holding AG	29.75	-0.07	-0.23%
PFE Pfizer Inc	27.18	UNCH	UNCH
SNY Sanofi SA	50.03	UNCH	UNCH
AMGN Amgen Inc	277.37	UNCH	UNCH